Bavarian Nordic is a fully integrated biotechnology company developing, manufacturing and commercializing novel vaccines for the prevention of life-threatening infectious diseases and the treatment of cancer. It focuses on diseases for which the unmet medical need is high and for which the natural power of the human body can be harnessed to induce an immune response. The Company’s live virus vaccine platform employs poxviruses in a modular approach to create its vaccines. This platform has generated one commercial product for smallpox, one Phase III immunotherapy candidate for prostate cancer, one Phase III candidate for Ebola and several other clinical programs in the areas of infectious disease and cancer immunotherapy. The Company’s vaccines are designed to enhance the immune system through the production of antibodies and the stimulation of T-cells. The Company optimizes poxviruses with proprietary technology and incorporates constructs with an antigen. In order to create recombinant viral vaccines, it employs these viruses in various combinations for both the initial vaccination, or primer, and subsequent vaccination(s), or booster(s). Its vaccine expertise has led to a 10+ year long relationship with the U.S. government, pursuant to which it has been awarded more than $1.2 billion in contracts. More recently, its platform has been validated by commercial relationships with two large pharmaceutical companies, specifically BMS for PROSTVAC, its Phase III cancer immunotherapy candidate, and Janssen (a J&J company) for its Ebola vaccine candidate and HPV vaccine candidate. It works closely with the NCI and the National Institutes of Health, or NIH, towards the development of key technologies underlying its product candidates.